Treatment for advanced differentiated thyroid cancer with multiple distant me-tastases (case report)

Carcinogenesis is a polypathogenetic process, and monotherapy of cancer, in particular metastatic clearly inadequate. This case report illustrates medical errors the management advanced differentiated thyroid cancer 51-year-old woman. Due to rarity such patients, specialists chose wrong strategy, i.e., thyroidectomy was not performed (e.g., origin metastases removed), radioiodine therapy categorically denied (although it first-line treatment for patients), brain were ablated, suppressive with levothyroxine prescribed. A protein kinase inhibitor antitumor activity, lenvatinib, prescribed cancer. Meanwhile, this medication used resistance that could be established Lenvatinib has many complications, including fatal ones, course can completed ≈25% only. Poorly controlled hypertension immediately developed after staring protease inhibitor. The pros cons new group anticancer medications, tyrosine inhibitors, are described detail. Pos-sible outcomes addressed. KEYWORDS: papillary I-131 radiotherapy, metastasis. FOR CITATION: Tereshchenko I.V. Treatment multiple distant me-tastases (case report). Russian Medical Inquiry. 2023;7(6):387–390 (in Russ.). DOI: 10.32364/2587-6821-2023-7-6-8.